0.75
Schlusskurs vom Vortag:
$0.7217
Offen:
$0.7275
24-Stunden-Volumen:
584.29K
Relative Volume:
0.35
Marktkapitalisierung:
$24.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-98.79M
KGV:
-0.2294
EPS:
-3.27
Netto-Cashflow:
$-51.66M
1W Leistung:
+17.30%
1M Leistung:
+163.99%
6M Leistung:
-75.17%
1J Leistung:
-75.33%
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Firmenname
Relmada Therapeutics Inc
Sektor
Branche
Telefon
646 876 3459
Adresse
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Vergleichen Sie RLMD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
3.03 | 0 | 0 | 0 | 0 | 0.00 | |
![]()
GOODO
Gladstone Commercial Corporation
|
20.43 | 372.90M | 0 | 0 | 0 | 0.00 |
![]()
JUNE
Dhandho Junoon Etf
|
11.50 | 190.93M | 0 | 0 | 0 | 0.00 |
![]()
SHMD
Schmid Group N V
|
2.76 | 131.34M | 0 | 0 | 0 | 0.00 |
![]()
PSNYW
Polestar Automotive Holding Uk
|
0.1601 | 350.74M | 2.07B | -1.42B | -1.37B | -0.6765 |
![]()
MOBBW
Mobilicom Limited Warrants
|
0.4197 | 636.80M | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-05 | Herabstufung | Mizuho | Outperform → Neutral |
2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
2024-06-05 | Herabstufung | Goldman | Neutral → Sell |
2022-10-14 | Herabstufung | Goldman | Buy → Neutral |
2022-10-14 | Herabstufung | Guggenheim | Buy → Neutral |
2022-10-14 | Herabstufung | Truist | Buy → Hold |
2022-10-13 | Herabstufung | Oppenheimer | Outperform → Perform |
2021-11-18 | Eingeleitet | Mizuho | Buy |
2021-05-20 | Fortgesetzt | Goldman | Buy |
2020-10-28 | Herabstufung | Goldman | Buy → Neutral |
2020-07-14 | Eingeleitet | Oppenheimer | Outperform |
2020-05-04 | Eingeleitet | SunTrust | Buy |
2020-04-21 | Eingeleitet | Goldman | Buy |
2020-01-27 | Eingeleitet | Jefferies | Buy |
2020-01-10 | Eingeleitet | SVB Leerink | Outperform |
2019-12-16 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten
Relmada Therapeutics Holds Annual Stockholders Meeting - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Lowered to Strong Sell Rating by Wall Street Zen - Defense World
RELMADA THERAPEUTICS Executives Make Significant Stock Purchases in May 2025 - TradingView
Relmada Therapeutics Executives Make Bold Stock Purchases! - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail
Relmada Therapeutics’ Earnings Call: Promising Data Amid Financial Concerns - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Relmada Therapeutics’ Q1 2025 results miss EPS expectations - Investing.com
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... - Yahoo Finance
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights - GuruFocus
Relmada Therapeutics Reports Q1 2025 Financial Results - TipRanks
Relmada Therapeutics to Report First Quarter 2025 Financial Resu - GuruFocus
Relmada Therapeutics (RLMD) Expected to Announce Earnings on Monday - Defense World
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - The Manila Times
Relmada Therapeutics, Inc. Announces Conference Call to Discuss Q1 2025 Financial Results and Business Progress - Nasdaq
Renaissance Technologies LLC Buys 138,625 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World
Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com
It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News
AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News
Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX
Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - EIN News
Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com
Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com
Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com
Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada
Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com
SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow
Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider
Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan
Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus
Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus
Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq
Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Stock Performance Spotlight: Relmada Therapeutics Inc (RLMD) Ends the Day at 0.74, Up by 6.86 - DWinneX
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - The Manila Times
Bridgeline Digital Secures Elite SOC 2 Type II Certification: What This Means for Enterprise Security - Stock Titan
Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - Sete News
RLMD’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Relmada Therapeutics Inc (RLMD) receives a Neutral rating from Mizuho - knoxdaily.com
RLMD Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Relmada Therapeutics (NASDAQ:RLMD) Trading Down 0.8% – Should You Sell? - Defense World
Finanzdaten der Relmada Therapeutics Inc-Aktie (RLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Relmada Therapeutics Inc-Aktie (RLMD) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
Shenouda Maged | Chief Financial Officer |
May 20 '25 |
Buy |
0.52 |
60,000 |
31,422 |
288,335 |
Shenouda Maged | Chief Financial Officer |
May 16 '25 |
Buy |
0.44 |
50,000 |
22,100 |
138,335 |
Ence Chuck | CA and CO |
May 16 '25 |
Buy |
0.45 |
228,961 |
103,330 |
267,931 |
TRAVERSA SERGIO | Chief Executive Officer |
May 20 '25 |
Buy |
0.56 |
147,686 |
82,246 |
734,024 |
TRAVERSA SERGIO | Chief Executive Officer |
May 16 '25 |
Buy |
0.45 |
172,314 |
77,472 |
556,338 |
TRAVERSA SERGIO | Chief Executive Officer |
May 19 '25 |
Buy |
0.50 |
30,000 |
14,994 |
586,338 |
TRAVERSA SERGIO | Chief Executive Officer |
Sep 11 '24 |
Buy |
2.99 |
51,407 |
153,707 |
384,024 |
TRAVERSA SERGIO | Chief Executive Officer |
Sep 09 '24 |
Buy |
2.71 |
55,579 |
150,619 |
299,603 |
TRAVERSA SERGIO | Chief Executive Officer |
Sep 10 '24 |
Buy |
2.75 |
33,014 |
90,788 |
332,617 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):